Reviva Pharmaceuticals (NASDAQ:RVPH) Raised to Buy at Maxim Group

Reviva Pharmaceuticals (NASDAQ:RVPH) was upgraded by equities research analysts at Maxim Group from a “hold” rating to a “buy” rating in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a $7.00 price target on the stock. Maxim Group’s price objective would suggest a potential upside of 272.34% from the stock’s current price.

A number of other research firms also recently weighed in on RVPH. EF Hutton Acquisition Co. I upgraded Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 23rd. Roth Mkm began coverage on Reviva Pharmaceuticals in a research report on Friday. They issued a “buy” rating and a $7.00 price objective for the company. Four research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $11.25.

Reviva Pharmaceuticals Price Performance

RVPH stock opened at $1.88 on Friday. The company has a 50 day moving average price of $1.56 and a 200 day moving average price of $1.29. Reviva Pharmaceuticals has a fifty-two week low of $0.60 and a fifty-two week high of $4.83. The stock has a market capitalization of $62.87 million, a PE ratio of -1.69 and a beta of -0.12.

Institutional Investors Weigh In On Reviva Pharmaceuticals

A hedge fund recently raised its stake in Reviva Pharmaceuticals stock. Geode Capital Management LLC increased its position in shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 278,496 shares of the company’s stock after acquiring an additional 42,376 shares during the quarter. Geode Capital Management LLC owned about 0.83% of Reviva Pharmaceuticals worth $401,000 as of its most recent SEC filing. 63.18% of the stock is currently owned by institutional investors.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.